Accordingly, some RIPK1 kinase inhibitors are now in phase I clinical trials for ALS and phase II clinical trials for psoriasis, rheumatoid arthritis, and ulcerative colitis [48], but to date no pharmacological inhibitor of RIPK1-mediated cell death is approved for regular clinical use. Here, RIPK1 is linked to ulcerative colitis.